CMS says new Part B drug plan would drop costs, but drug makers have to play along
CMS says its new “International Pricing Index (IPI) model” test will lower prices for patients and increase provider surcharges on those drugs in some parts of the U.S. starting in 2020. But some experts are skeptical the model will work.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.
Quick, Current, Complete - www.findacode.com